GlassScriptPhysician profile
Veena Subramanian
NPI 1114991189
$20,179.34
in general payments reported to CMS, 2019-2025
75 companies · $5,024 in 2025
The $5,024 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,080 · 2020: $1,304 · 2021: $1,565 · 2022: $2,684 · 2023: $4,075 · 2024: $4,447 · 2025: $5,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,445.65 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,068.47 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $1,658.79 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ucb, INC. | $1,369.82 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Alexion Pharmaceuticals, INC. | $911.38 | 2019-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $889.86 | 2020-2025 | Ingrezza, Ongentys |
| Catalyst Pharmaceuticals, INC. | $804.61 | 2023-2025 | Fycompa, Firdapse |
| Argenx US, INC. | $783.37 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Ani Pharmaceuticals, INC. | $777.28 | 2023-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $684.13 | 2023-2025 | |
| Lilly USA, LLC | $602.61 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Emd Serono, INC. | $518.99 | 2019-2025 | Mavenclad |
| Biogen, INC. | $486.99 | 2019-2025 | Leqembi, Skyclarys |
| Amgen INC. | $473.11 | 2020-2025 | Uplizna |
| Eisai INC. | $469.76 | 2019-2025 | |
| Genzyme Corporation | $450.44 | 2019-2023 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veena Subramanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.